Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Biochemical Pharmacology|November 27, 2013
Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020Harald Hampel, Simone Lista, Stefan J Teipel, et al.
The Lancet. Neurology|May 2, 2021
Clinical diagnosis of Alzheimer's disease: recommendations of the International Working GroupBruno Dubois, Nicolas Villain, Giovanni B Frisoni, et al.
Neurology|February 16, 2018
Cerebral microbleeds and CSF Alzheimer biomarkers in primary progressive aphasiasAline Mendes, Anne Bertrand, Foudil Lamari, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|May 19, 2020
The influence of diversity on the measurement of functional impairment: An international validation of the Amsterdam IADL Questionnaire in eight countriesMark A Dubbelman, Merike Verrijp, David Facal, et al.
Acta Neuropathologica|June 7, 2021
Clinical and neuropathological diversity of tauopathy in MAPT duplication carriersDavid Wallon, Susana Boluda, Anne Rovelet-Lecrux, et al.
The Lancet. Neurology|May 23, 2014
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteriaBruno Dubois, Howard H Feldman, Claudia Jacova, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 26, 2016
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteriaBruno Dubois, Harald Hampel, Howard H Feldman, et al.
Journal of Alzheimer'S Disease : JAD|August 6, 2019
Causative Mutations and Genetic Risk Factors in Sporadic Early Onset Alzheimer's Disease Before 51 YearsMorgane Lacour, Olivier Quenez, Anne Rovelet-Lecrux, et al.
Plos Medicine|March 29, 2017
APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic casesHélène-Marie Lanoiselée, Gaël Nicolas, David Wallon, et al.
Pageof 8